A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4. Background: CD4+ regulatory T cells (Tregs) ...
“Taken together, our studies suggest that 2B010 represents an anti-CD25 mAb with unique properties in that it deleted Treg from an inflammatory environment (GVHD) as well as from the TME” “Taken ...
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...
3D rendering of the tumor microenvironment. The recipe for a general and long-lasting cancer treatment could involve regulatory T cells, a type of white blood cell. This is the first installment in a ...
Vaccination of metastatic prostate cancer patients using mature dendritic cells transfected with mRNA encoding hTERT or an MHC class II targeted hTERT/LAMP fusion protein: Results from a phase I ...
A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled "A novel anti-human CD25 mAb with preferential reactivity to activated T regulatory cells depletes them from the ...
Study met Primary and Secondary Endpoints for Safety and Regulatory T cell (Treg) Cell Population Enhancement, respectively, with no off-target effects on T effector lymphocytes, providing further ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results